[go: up one dir, main page]

PE47696A1 - Cristal de glicosido de espiroestanilo - Google Patents

Cristal de glicosido de espiroestanilo

Info

Publication number
PE47696A1
PE47696A1 PE1995277474A PE27747495A PE47696A1 PE 47696 A1 PE47696 A1 PE 47696A1 PE 1995277474 A PE1995277474 A PE 1995277474A PE 27747495 A PE27747495 A PE 27747495A PE 47696 A1 PE47696 A1 PE 47696A1
Authority
PE
Peru
Prior art keywords
fluorofenilcarbamoil
espiroestan
celobiosil
oxi
ona
Prior art date
Application number
PE1995277474A
Other languages
English (en)
Inventor
Sr Richard A Buzon
Jr Harry A Watson
Michael P Deninno
Douglas J Allen
Jonathan B Zung
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE47696A1 publication Critical patent/PE47696A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE AL COMPUESTO DE FORMULA: (3�,5O,25R)-3-[(�-D-4",6"-BIS-[2-FLUOROFENILCARBAMOIL]CELOBIOSIL)OXI]ESPIROESTAN-12-ONA Y SUS DOS FORMAS CRISTALINAS (FORMA A Y FORMA B), QUE TIENEN SEPARACIONES d POR DIFRACCION DE RAYOS X TALES COMO: a) PARA LA FORMA A, DE 21,10 A 3,37, CONSIDERANDO LOS VEINTE PICOS MAS ALTOS; b) PARA LA FORMA B, DE 19,96 A 3,37, CONSIDERANDO LOS DOCE PICOS MAS ALTOS; TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION QUE COMPRENDE LA MEZCLA DE (3�,5O,25R-3-[(�-D-4", 6"-BIS-[2-FLUOROFENILCARBAMOIL]CELOBIOSIL)OXI]-ESPIROESTAN-12 ONA EN ACETATO DE ETILO, ACETONITRILO O UN ALCANOL DE C1-C4, Y LUEGO DEJAR QUE SE FORME LA (3�,5O,25R)-3-[(�-D-4",6"-BIS-[2-FLUOROFENILCARBAMOIL]CELOBIOSIL)OXI]-ESPIROESTAN-12 ONA-CRISTALINA. ESTE COMPUESTO ES USADO EN EL TRATAMIENTO DE HIPERCOLESTEROLEMIA O LA ATEROESCLEROSIS
PE1995277474A 1994-08-30 1995-08-28 Cristal de glicosido de espiroestanilo PE47696A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29810694A 1994-08-30 1994-08-30

Publications (1)

Publication Number Publication Date
PE47696A1 true PE47696A1 (es) 1996-11-12

Family

ID=23149057

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995277474A PE47696A1 (es) 1994-08-30 1995-08-28 Cristal de glicosido de espiroestanilo

Country Status (20)

Country Link
US (1) US5804562A (es)
EP (1) EP0778846A1 (es)
JP (1) JPH09510735A (es)
KR (1) KR970705574A (es)
AU (1) AU2265395A (es)
BR (1) BR9503827A (es)
CA (1) CA2198097A1 (es)
CO (1) CO4480032A1 (es)
FI (1) FI970828A7 (es)
HR (1) HRP950459A2 (es)
IL (1) IL115062A0 (es)
MA (1) MA23651A1 (es)
MX (1) MX9701525A (es)
NO (1) NO970910L (es)
OA (1) OA10402A (es)
PE (1) PE47696A1 (es)
PL (1) PL318937A1 (es)
SI (1) SI9520092A (es)
TR (1) TR199501065A2 (es)
WO (1) WO1996006854A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1066042T3 (da) * 1998-03-26 2006-12-18 Phytopharm Plc Steroidale saponiner til behandling af Alzheimers sygdom
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0796864A2 (en) * 1992-06-26 1997-09-24 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
CA2180149A1 (en) * 1993-12-28 1995-07-06 Michael Paul Deninno Steroidal glycosides

Also Published As

Publication number Publication date
EP0778846A1 (en) 1997-06-18
BR9503827A (pt) 1996-09-10
NO970910D0 (no) 1997-02-27
MA23651A1 (fr) 1996-04-01
SI9520092A (en) 1997-12-31
KR970705574A (ko) 1997-10-09
MX9701525A (es) 1997-05-31
HRP950459A2 (en) 1997-08-31
US5804562A (en) 1998-09-08
CA2198097A1 (en) 1996-03-07
OA10402A (en) 2001-12-05
NO970910L (no) 1997-02-27
WO1996006854A1 (en) 1996-03-07
CO4480032A1 (es) 1997-07-09
FI970828A0 (fi) 1997-02-27
AU2265395A (en) 1996-03-22
TR199501065A2 (tr) 1996-06-21
PL318937A1 (en) 1997-07-21
IL115062A0 (en) 1995-12-08
FI970828L (fi) 1997-02-27
JPH09510735A (ja) 1997-10-28
FI970828A7 (fi) 1997-02-27

Similar Documents

Publication Publication Date Title
ES2131207T3 (es) Derivados de amidas del acido valproico y 2-valproenoico y su uso como anticonvulsivos.
AR038045A1 (es) Agentes terapeuticos
BR9916282A (pt) Composto, uso de um um composto e método de tratamento
HUT72436A (en) Process for the production of imidazopyridines and pharmaceutical compositions containing them and which are suitable for treating gastro-intestinal diseases
AR021482A1 (es) Compuestos de 4-carboxiamino-1,2,3,4-tetrahidroquinolinas, composiciones farmaceuticas, kit, y uso de los mismos.
AU7585091A (en) Novel derivative of caffeic acid, oraposide, cosmetic or pharmaceutical, particularly dermatological, composition containing it
PE47696A1 (es) Cristal de glicosido de espiroestanilo
ES466856A1 (es) Procedimiento para la preparacion de compuestos derivados dela pirrolidin-2-ona.
CU23101A3 (es) Ácidos 3-propil gamma-aminobutírico mono y disustituidos
ATE26274T1 (de) Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung.
ATE10626T1 (de) N-substituierte omega-(2-oxo-imidazolin-1-yl)alkans[uren, deren salze und ester, verfahren zu deren herstellung und diese aktiven substanzen enthaltende pharmazeutische zubereitungen.
MX2024015708A (es) Moduladores del trem2
ES2188743T3 (es) Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos.
ES2079832T3 (es) Acido quenodeoxicolico o acido ursodeoxicolico para el tratamiento de enfermedades de los organos respiratorios.
DK0629635T3 (da) Hidtil ukendte 19-nor-11beta-phenoxysulfonamid- eller 11beta-phenoxysulfonylureasteroider, fremgangsmåde og mellemprodukter til deres fremstilling, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf
RU98121401A (ru) Новые аналоги витамина d
IT8049625A0 (it) Composizione per il trattamento di stati patologici come osteoporosi esimili
DK39084A (da) 2-imino-pyrrolidiner, fremgangsmaade til deres fremstilling og terapeutiske midler indeholdende dem
NO151410C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive n-(2-klorethyl)-n-nitrosourea-forbindelser
MX9203577A (es) Nuevos derivados de sinergistinas y composiciones farmaceuticas que los contienen.
ES471672A1 (es) Un procedimiento para la preparacion de un peptido
ATE10841T1 (de) Tricyclische thiazolyloxamidsaeuren und derivate, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
ES8900107A1 (es) Un procedimiento para preparar derivados de alcanoles heteropoliciclicos
DK0571593T3 (da) Nye ikke-ioniske ioderede midler til røntgenstrålekontrast, fremgangsmåde til deres fremstilling og galeniske præparater indeholdende dem
ES2054790T3 (es) Compuestos que tienen actividad cardiovascular.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal